



ORIGINAL ARTICLE

Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis



Walter Masson^{a,b,*}, Martín Lobo^{a,c}, Augusto Lavallo-Cobo^{a,d}, Graciela Molinero^a

^a Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Azcuena 980, C1115AAD Buenos Aires, Argentina

^b Cardiology Department, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 (C1199ABB), Buenos Aires, Argentina

^c Cardiology Department, Hospital Militar Campo de Mayo, Tte. Gral. Ricchieri S/N (B1659AMA), Buenos Aires, Argentina

^d Cardiology Department, Sanatorio Finochietto, Av. Córdoba 2678 (C1187AAN), Buenos Aires, Argentina

Received 5 July 2020; accepted 7 September 2020

Available online 13 December 2020

KEYWORDS

Bempedoic acid;
Low-density lipoprotein cholesterol;
Non-high-density lipoprotein cholesterol;
Apolipoprotein B;
High-sensitivity C-reactive protein;
Meta-analysis

Abstract

Background: Bempedoic acid is a novel non-statin drug that was developed to treat hyperlipidemia in combination with other lipid-lowering drugs in those patients who need additional lipid lowering.

Objectives: (1) To investigate the lipid efficacy of bempedoic acid; (2) to analyze the anti-inflammatory effects of bempedoic acid estimated through high sensitivity C-reactive protein (hsCRP).

Methods: We performed a meta-analysis including randomized trials of bempedoic acid therapy, reporting low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B and hsCRP with a minimum of 4 weeks of follow-up. The primary endpoint was defined as the percentage change in lipids and hsCRP levels measured from baseline to follow-up, comparing groups of subjects on bempedoic acid versus placebo.

Results: Seven eligible trials of bempedoic acid (3892 patients) were included. The bempedoic acid therapy was associated with a significant reduction in LDL-C levels [−20.3% (CI 95% −23.5 to −17.1)]; $I^2 = 43%$. Similarly, a significant percentage reduction in the apolipoprotein B levels [−14.3% (CI 95% −16.4 to −12.1)]; $p < 0.05$; $I^2 = 46%$, non-HDL-C levels [−15.5% (CI 95% −18.1 to −13.0)]; $p < 0.05$; $I^2 = 53%$ and hsCRP [−23.4% (CI 95% −32.6 to −14.2)]; $p < 0.05$; $I^2 = 69%$ was demonstrated with the bempedoic acid use. The sensitivity analysis showed that the results were robust.

* Corresponding author.

E-mail address: walter.masson@hospitalitaliano.org.ar (W. Masson).

Conclusion: Our data suggests that the use of bempedoic acid significantly reduces the levels of all atherogenic lipid markers, including LDL-C, non-HDL-C and apolipoprotein B. Furthermore, considering hsCRP levels, the drug produces an anti-inflammatory effect.

© 2020 Sociedad Española de Arteriosclerosis. Published by Elsevier España, S.L.U. All rights reserved.

PALABRAS CLAVE

Ácido bempedoico;
Colesterol de lipoproteína de baja densidad;
Colesterol de lipoproteína de no alta densidad;
Apolipoproteína B;
Proteína C reactiva de alta sensibilidad;
Meta-análisis

Efecto del ácido bempedoico en los índices aterogénicos de los lípidos y la inflamación: meta-análisis

Resumen

Antecedentes: El ácido bempedoico es un fármaco nuevo no perteneciente al grupo de las estatinas, que fue desarrollado para tratar la hiperlipidemia, junto con otros fármacos liporredutores, en aquellos pacientes que necesitan una reducción lipídica adicional.

Objetivos: (1) Estudiar la eficacia anti-lipídica del ácido bempedoico; (2) analizar los efectos antiinflamatorios del ácido bempedoico, calculados a través de la proteína C reactiva de alta sensibilidad (hsCRP).

Métodos: Realizamos un meta-análisis incluyendo ensayos aleatorios de terapia de ácido bempedoico, reportando colesterol de lipoproteína de baja densidad (LDL-C), colesterol de lipoproteína de no alta densidad (no-HDL-C), apolipoproteína B y hsCRP con un mínimo de 4 semanas de seguimiento. El objetivo primario se definió como el cambio porcentual de lípidos y niveles de hsCRP medidos desde el inicio hasta el seguimiento, comparando los sujetos de los grupos ácido bempedoico frente a placebo.

Resultados: Se incluyeron siete ensayos elegibles de ácido bempedoico (3.892 pacientes). La terapia de ácido bempedoico se asoció a una reducción significativa de los niveles de LDL-C [$-20,3\%$ (IC 95% de $-23,5$ a $-17,1$); $I^2 = 43\%$]. De igual modo, se demostró una reducción porcentual significativa de los niveles de apolipoproteína B [$-14,3\%$ (IC 95% de $-16,4$ a $-12,1$); $p < 0,05$; $I^2 = 46\%$], niveles de no-HDL-C [$-15,5\%$ (IC 95% de $-18,1$ a -13); $p < 0,05$; $I^2 = 53\%$] y hsCRP [$-23,4\%$ (IC 95% de $-32,6$ a $-14,2$); $p < 0,05$; $I^2 = 69\%$] con el uso de ácido bempedoico, reflejando el análisis de sensibilidad que los resultados eran sólidos.

Conclusión: Nuestros datos sugieren que el uso de ácido bempedoico reduce significativamente los niveles de todos los marcadores lipídicos aterogénicos, incluyendo LDL-C, no-HDL-C y la apolipoproteína B. Además, considerando los niveles de hsCRP, el fármaco produce un efecto antiinflamatorio.

© 2020 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Many patients do not achieve the low-density lipoprotein cholesterol (LDL-C) targets recommended in the current guidelines, even with the use of statins and ezetimibe.¹ The muscular effects could be one of the reasons that causes low adherence to statins. The introduction of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors is an alternative to hypercholesterolemia therapies, but its use was limited by the high cost. Consequently, new lipid-lowering strategies are necessary in order to reduce the residual cardiovascular risk in patients who, despite receiving maximum tolerated lipid-lowering therapy, do not achieve the recommended lipid goals. Hence, there is a growing interest in develop drugs with a statin-like mechanism of action but associated with less or none muscular side effects. Consequently, new lipid-lowering strategies are necessary to reduce residual cardiovascular risk

Bempedoic acid is a non-statin lipid-lowering drug developed for the treatment of hypercholesterolaemia.² It is a

prodrug that requires activation by the enzyme very long-chain acyl-coA synthetase 1 present in the liver but absent in most other tissues. It lowers LDL-C by inhibiting ATP citrate lyase (ACL), an enzyme involved in cholesterol biosynthesis, which acts upstream of 3-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase.³

Mendelian randomization of large human study cohorts has validated ACL inhibition as a target for LDL-C lowering and atheroprotection.⁴ Several phase 2 and 3 clinical trials revealed that bempedoic acid effectively reduce LDL-C as monotherapy, combined with ezetimibe, added to statin therapy and in statin-intolerant hypercholesterolemic patients.⁵⁻¹¹

Based on positive findings in these clinical trials, bempedoic acid was approved in the USA and in the EU as monotherapy and as a fixed-dose combination with ezetimibe.¹²

Accumulating evidence suggests that inflammation plays an important role in the pathophysiology of atherosclerotic plaque stabilization and thromboembolism, with

inflammatory cells being involved in all stages of atherosclerosis development. Therefore, anti-inflammatory properties of lipid-lowering drugs would contribute in plaque stabilization and in the prevention of thromboembolic events.¹³

A previously published meta-analysis has evaluated the lipid effects of bempedoic acid use.¹⁴ However, only five phase 2 studies were included, many of which used lower doses of bempedoic acid than currently recommended. The multiple phase 3 studies that have been published in the last two years were not included. Also, the anti-inflammatory effect was not evaluated in the analysis.

Therefore, the objectives of the present meta-analysis were: (1) to investigate the lipid efficacy of bempedoic acid, analyzing all the evidence available to date; (2) to analyze the anti-inflammatory effects of bempedoic acid, estimated through high-sensitivity C-reactive protein (hsCRP).

Material and methods

Data extraction and quality assessment

Our meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting systematic reviews.¹⁵ A literature search was performed that identified clinical trials of bempedoic acid (ETC-1002) and published between January 2000 and April 2020. Two independent reviewers searched the electronic PubMed/MEDLINE, Embase, Google Scholar, Scielo and Cochrane Controlled Trials databases using the following terms: “bempedoic acid”, “ETC-1002” and “non-statin lipid-lowering therapy”, “cholesterol”, “dyslipidemia”, “hypercholesterolemia”, “heterozygous familial hypercholesterolemia”, “combined familial hyperlipidemia”, “elevated cholesterol levels”, “elevated cholesterol”, “lipoproteins”, “LDL-C”, “non-high-density lipoprotein cholesterol” (non-HDL-C), “apolipoprotein B” and “hsCRP”.

All the analyzed studies meet the following inclusion criteria: (a) Comparisons of efficacy of bempedoic acid versus placebo; (b) Follow-up duration ≥ 4 weeks; (c) Randomized clinical trials; (d) Reporting of change in lipids and hsCRP values between baseline and follow-up. The lipids evaluated were LDL-C, non-HDL-C and apolipoprotein B.

The primary endpoint of the study was defined as the percentage change in lipids and hsCRP levels measured from baseline to follow-up, comparing groups of subjects on bempedoic acid versus placebo. As a secondary exploratory endpoint, we evaluated the safety of bempedoic acid. The occurrence of muscular disorder (myalgia, muscle spasms, pain in extremity or muscular weakness), elevation of liver enzymes (alanine or aspartate aminotransferase level $> 3 \times \text{ULN}$), increased creatinine level, occurrence of gout and serious adverse events (results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormally defect or is an important medical event) were evaluated.

When the summary/dispersion measures were not mean and standard deviation, conversion tools previously suggested by the literature were used.¹⁶

Potential risks of bias were evaluated for all included trials, using the Cochrane tool developed for this purpose.¹⁷ This tool assesses bias in five different domains: bias arising from the randomization, bias due to deviations from intended intervention, bias due to missing outcome data, bias in measurement of the outcome and bias in selection of the reported result. Each domain was rated as “High”, “Low” or “Some concerns” depending on the judgment of each author following the recommendations.

Statistical analysis

The summary effect of bempedoic acid on lipids and hsCRP levels was estimated. Measures of effect size were expressed as mean difference for the primary endpoint and as Odds Ratio (OR) for the secondary exploratory analysis, and the I^2 statistic was calculated to quantify between-trial heterogeneity and inconsistency. Meta-analyses were conducted using a fixed-effect model or a random-effect model based on the low ($< 40\%$) or moderately-high ($> 40\%$) inter-study heterogeneity. The level of statistical significance was set at a two-tailed alpha of 0.05. Statistical analyses were performed using the R software for statistical computing version 3.5.1 with additional specific packages.¹⁸

Sensitivity analyses

The sensitivity analysis consists of replicating the results of the meta-analysis, excluding in each step one of the studies included in the review. If the results obtained are similar, both in direction and magnitude of the effect and statistical significance, it indicates that the analysis is robust.

Analysis of publication bias

A funnel plot using the standard error (SE) for mean difference was created, and Egger’s regression intercept tests were done.

Results

Seven eligible trials of bempedoic acid, including 3892 patients, were identified and considered eligible for the analyses. All these studies were taken into account for the analysis of non-HDL-C and apolipoprotein B. In this case, there was a total of 2589 subjects allocated to receive bempedoic acid and 1303 subjects allocated to the respective placebo group. Six studies were included for the analysis of LDL-C and five trials for hsCRP analysis because these data were reported. A flow diagram of the study’s screening process has been shown in Fig. 1.

All studies evaluated were randomized clinical trials and had a placebo group. The quality of the studies evaluated can be seen in Fig. 2.

Of the total of studies, five were phase 3 and two were phase 2 studies. Two studies included dyslipidemic patients and two others included statin intolerant subjects. Likewise, two studies included adults with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia

Table 1 Characteristics of the studies included in the analysis.

Study	Treatment arm	N	Control arm	N	Population description	Follow-up (weeks)	Background lipid-lowering therapy
CLEAR Harmony ⁵	Bempedoic acid (180 mg/day)	1488	Placebo	742	ASCVD and/or HeFH LDL-C > 70 mg/dl	12	Maximally tolerated statin therapy
CLEAR Serenity ⁶	Bempedoic acid (180 mg/day)	224	Placebo	107	Statin intolerance LDL-C > 130 mg/dl (primary prevention) LDL-C > 100 mg/dl (ASCVD or HeFH)	24	None or low-dose statin
CLEAR Wisdom ⁷	Bempedoic acid (180 mg/day)	522	Placebo	257	ASCVD and/or HeFH LDL-C > 70 mg/dl	12	Maximally tolerated statin therapy
CLEAR Tranquility ⁸	Bempedoic acid (180 mg/day)	181	Placebo	88	Statin intolerance C-LDL > 100 mg/dl	12	Ezetimibe ± low-dose statin
Ballantyne et al., 2020 ⁹	Bempedoic acid (180 mg/day)	88	Placebo	41	ASCVD, HeFH or multiple CV risk factors	12	Statins
Ballantyne et al., 2016 ¹⁰	Bempedoic Acid (180 mg/day)	45	Placebo	45	Hypercholesterolemia	12	Statins
Lalwani et al. ¹¹	Bempedoic acid (180 mg/day)	41	Placebo	23	Hypercholesterolemia	4	Atorvastatin 80 mg/day

ASCVD: atherosclerotic cardiovascular disease; CV: cardiovascular; HeFH: Heterocygous Familial Hypercholesterolemia; LDL-C: low density lipoprotein cholesterol.




Figure 1 Flow diagram of the study screening process.

or both. One study included, in addition to these patients, subjects with multiple cardiovascular risk factors. In all trials, the patients were eligible to participate if they had been taking stable doses of maximally tolerated statin therapy either alone or in combination with other lipid-lowering therapies and if they had a LDL-C level above the threshold defined in each study. In most cases, this LDL-C threshold ranged from 70 to 100 mg/dl in patients with cardiovascular disease or heterozygous familial hypercholesterolemia and from 100 to 130 mg/dl in subjects in primary prevention. The follow-up ranged between 4 and 24 weeks. The characteristics of the studies included in the analysis can be seen in Table 1.

This meta-analysis showed that bempedoic acid was associated with a significant percentage reduction in LDL-C levels [−20.3% (CI 95% −23.5 to −17.1)]; $p < 0.05$; $I^2 = 43\%$. Similarly, a significant percentage reduction in the apolipoprotein B levels [−14.3% (CI 95% −16.4 to −12.1)]; $p < 0.05$; $I^2 = 46\%$ and non-HDL-C levels [−15.5% (CI 95% −18.1 to −13.0)]; $p < 0.05$; $I^2 = 53\%$ was demonstrated with the bempedoic acid use.

On the other hand, bempedoic acid was associated with a significant percentage reduction in hsCRP levels [−23.4% (CI 95% −32.6 to −14.2)]; $p < 0.05$; $I^2 = 69\%$].

The graphic representation of the effect of bempedoic acid on lipid and inflammatory markers can be seen in Figs. 3 and 4.

Bempedoic acid therapy showed a similar rate of serious adverse events (OR, 1.09; 95% CI, 0.89–1.33; $I^2 = 0\%$) and muscle-related adverse events (OR, 0.99; 95% CI, 0.76–1.29; $I^2 = 0\%$) compared to placebo. However, the use of bempedoic acid was more frequently associated with an increase in liver enzymes (OR, 3.09; 95% CI, 1.13–8.45; $I^2 = 0\%$), creatinine level (OR, 2.65; 95% CI, 1.06–6.60; $I^2 = 0\%$) and the incidence of gout (OR, 3.05; 95% CI, 1.23–7.55; $I^2 = 32\%$). The graphic representation of the main adverse effects can be seen in the supplementary material (Figs. S1 and S2).

The funnel plot of standard error by mean difference of endpoints did not suggest publication bias (Fig. 5). In the same way, Egger's regression intercept tests gave a p value of 0.25, not indicating possible publication bias.

The sensitivity analysis showed that the results were robust (Fig. 6).

Discussion

In this meta-analyses, which included the phase 3 studies from the CLEAR program, bempedoic acid therapy compared




Figure 2 Summary and individual bias assessment of included studies.

with placebo was associated with a significant reduction in the levels of all atherogenic lipoproteins and inflammatory markers such as hsCRP.

Dyslipidemia is a critical predisposing factor for the development of cardiovascular diseases. Statins competitively inhibit HMGCoA reductase, the rate-limiting enzyme in cholesterol synthesis. In response, a compensatory upregulation in hepatic LDL receptor cell surface expression

occurs, leading to a reduction in circulating LDL-C by 30–50%.¹⁹ Recently published cholesterol treatment guidelines emphasize the use of statins as the preferred treatment strategy for both primary and secondary prevention of cardiovascular disease.^{1,20} However, despite the widespread prescription of these drugs, adherence to statin therapy is a major challenge worldwide. The most common adverse events of statins are muscle related and are the main




Figure 3 Effect of Bempedoic acid on LDL-C and hsCRP. Random effects, mean difference, 95% confidence intervals (CI) and I^2 statistics. Dif: difference; hsCRP: high-sensitivity C-reactive protein.




Figure 4 Effect of Bempedoic acid on non-HDL-C and apolipoprotein B. Random effects, mean difference, 95% confidence intervals (CI) and I^2 statistics. Dif: difference.

reason for statin non-adherence and/or discontinuation.^{21,22} Thus, patients who cannot tolerate a statin-based treatment regimen present a challenge for lipid management and cardiovascular event risk reduction.

Medical societies have released guidelines to address the appropriate use of non-statin therapies.^{21–23} These guidelines incorporated new evidence, including IMPROVE-IT, FOURIER and ODYSSEY OUTCOMES clinical trials, which showed that the combination of statin therapy with other non-statin agents such as ezetimibe or PCSK9 inhibitors had a significant clinical benefit.^{24–26} However, the modest effect of ezetimibe or the high cost of PCSK9 inhibitors means that the problem has not yet been resolved.

Bempedoic acid is a novel, non-statin, oral drug being developed for the treatment of hyperlipidemia in combination with other lipid-lowering drugs in patients who need additional lipid lowering.² Similar to statins, the predominant mechanism of action of bempedoic acid is through increased LDL receptor activity and consequent reduction in the plasma concentration of LDL-C. Unlike statins, bempedoic acid's mechanism of action is to impair cholesterol synthesis through ACL inhibition which acts upstream

of HMGCoA reductase. Furthermore, bempedoic acid is a prodrug that becomes activated by an enzyme expressed primarily in the liver, allowing it to avoid the potential myotoxicity associated with statin therapy.

This meta-analysis jointly investigated the lipid-lowering effect on the main atherogenic particles and the anti-inflammatory effect of bempedoic acid. Our analysis showed that on average the use of bempedoic acid decreased LDL-C by 20%.

The efficacy of bempedoic acid depends on concomitant treatment. The lipid-lowering response is greater when it is used as monotherapy or in combination with ezetimibe than when it is combined with statins. This could explain why the efficacy in lowering LDL-C was greater in CLEAR-Tranquility and CLEAR-Serenity studies compared to the rest of the trials.^{6,8}

A previously published meta-analysis found that the reduction of LDL-C was slightly higher (26.6%).¹⁴ However, this study included fewer patients (625) and analyzed different doses than those currently recommended (180 mg/day). Likewise, in our study we included several recently published phase 3 studies.




Figure 5 Funnel plot to assess publication bias. A: LDL-C; B: hsCRP; C: non-HDL-C; D: Apolipoprotein B.




Figure 6 Sensitivity analysis. After replicating the results of the meta-analysis, excluding in each step one of the studies included in the review, the results obtained are similar. A: LDL-C; B: hsCRP; C: non-HDL-C; D: Apolipoprotein B.

Although LDL-C is the main lipid target, the non-HDL-C and apolipoprotein B represents the total atherogenic particles better than LDL-C.^{27,28} In our study we also evaluated the impact of bempedoic acid on these lipid markers, showing similar findings to the C-LDL analysis.

Another relevant point of our meta-analysis is that the effect of bempedoic acid on hsCRP was evaluated. Anti-inflammatory properties of bempedoic acid were further investigated in primary human monocyte derived macrophages and in vivo models of inflammation. In

clinical studies, bempedoic acid has not only demonstrated improved lipid profiles but also revealed significantly attenuated levels of hsCRP, an independent risk factor for coronary artery disease.⁵⁻¹¹ Likewise, bempedoic acid regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMP-activated protein kinase.²⁹

Statins studies showed a reduction in hsCRP levels. In a sample of 472 participants included in the CARE trial, the use of pravastatin 40 mg exhibited a median reduction

of 17.4% on hsCRP levels.³⁰ Similar reduction was observed in the AFCAPS/TexCAPS where lovastatin 20 mg therapy, reduced levels by 14.8%.³¹ In the JUPITER trial, compared to placebo, use of rosuvastatin 20 mg showed a greater reduction (37%).³²

Consequently, the 23.4% reduction in hsCRP levels with the use of bempedoic acid showed in this meta-analysis could be relevant since it would add an additional cardiovascular benefit beyond lipids.

Our results showed that bempedoic acid therapy no significant increase serious adverse effects. In addition, bempedoic acid, due to its mechanism of action, does not increase the risk of muscle-related side-effects. However, an increase in blood levels of transaminases, creatinine and uric acid were observed with the use of bempedoic acid. Likewise, the occurrence of gout was three times higher with bempedoic acid compared to placebo. The observed increase in uric acid may be attributable to a potential competition between uric acid and the glucuronide metabolite of bempedoic acid for the same renal transporters, resulting in less urinary excretion of these substance.³³ In addition, the observed increase in uric acid might be due to glomerular filtration rate reduction by bempedoic acid. A recent meta-analysis specifically designed to analyze the association between bempedoic acid and elevated uric acid showed the same results.³⁴ On the other hand, the observed signs of renal damage may involve the exposure of glomerular and tubular structures to high uric acid levels.³⁵ New studies will be necessary to establish the clinical relevance of these adverse effects related to bempedoic acid.

This meta-analysis presents several limitations. First, they are related with clinical heterogeneity (popular characteristics, different schemes of lipid-lowering therapy, different follow-up). However, the statistical heterogeneity was low and the results were robust when performing the sensitivity analysis. Second, the analysis included only trial-level data without having the individual data. Finally, we did not perform the analysis with another primary endpoint, such as the absolute change of lipid and hsCRP levels, because we did not have these data in all the original publications.

Conclusion

Our data suggests that the use of bempedoic acid significantly reduces the levels of atherogenic lipid markers, including LDL-C, non-HDL-C and apolipoprotein B. Furthermore, considering hsCRP levels, the drug produces an anti-inflammatory effect. Future studies will demonstrate whether the lipid and anti-inflammatory effects of bempedoic acid could be associated with a reduction in vascular events.

Authors' contributions

Masson Walter was the main coordinator of the project and was responsible for the study design. Masson Walter and Lavalle-Cobo Augusto drafted the manuscript of the present paper. Masson Walter, Lobo Martín and Lavalle-Cobo Augusto were involved in the supervising of data collection and stratification. Lobo Martín and Masson Walter contributed to data

assembly and analysis. Molinero Graciela contributed with manuscript revision. All authors contributed intellectually to this manuscript and have approved this final version.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

None.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.arteri.2020.09.002>.

References

- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41:111–88, <http://dx.doi.org/10.1093/eurheartj/ehz455>.
- Niman S, Rana K, Reid J, Sheikh-Ali M, Lewis T, Choksi RR, et al. A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia. *Am J Cardiovasc Drugs*. 2020, <http://dx.doi.org/10.1007/s40256-020-00399-w>.
- Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. *Curr Opin Lipidol*. 2019;30:1–9, <http://dx.doi.org/10.1097/MOL.0000000000000565>.
- Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian randomization study of ACLY and cardiovascular disease. *N Engl J Med*. 2019;380:1033–42, <http://dx.doi.org/10.1056/NEJMoa1806747>.
- Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. *N Engl J Med*. 2019;380:1022–32, <http://dx.doi.org/10.1056/NEJMoa1803917>.
- Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. *J Am Heart Assoc*. 2019;8:e011662, <http://dx.doi.org/10.1161/JAHA.118.011662>.
- Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. *JAMA*. 2019;322:1780–8, <http://dx.doi.org/10.1001/jama.2019.16585>.
- Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. *Atherosclerosis*. 2018;277:195–203, <http://dx.doi.org/10.1016/j.atherosclerosis.2018.06.002>.
- Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated

- statin therapy. *Eur J Prev Cardiol.* 2020;27:593–603, <http://dx.doi.org/10.1177/2047487319864671>.
10. Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. *Am J Cardiol.* 2016;117:1928–33, <http://dx.doi.org/10.1016/j.amjcard.2016.03.043>.
 11. Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. *J Clin Lipidol.* 2019;13:568–79, <http://dx.doi.org/10.1016/j.jacl.2019.05.003>.
 12. Markham A. Bempedoic acid: first approval. *Drugs.* 2020;80:747–53, <http://dx.doi.org/10.1007/s40265-020-01308-w>.
 13. Li B, Li W, Li X, Zhou H. Inflammation: a novel therapeutic target/direction in atherosclerosis. *Curr Pharm Des.* 2017;23:1216–27, <http://dx.doi.org/10.2174/1381612822666161230142931>.
 14. Wang X, Luo S, Gan X, He C, Huang R. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. *Kardiol Pol.* 2019;77:207–16, <http://dx.doi.org/10.5603/KP.a2019.0013>.
 15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ.* 2009;339:b2700.
 16. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* 2014;14:135.
 17. Bukoh MX, Siah C-JR. A systematic review and meta-analysis on the structured handover interventions in improving patient safety outcomes. *J Nurs Manag.* 2020;28:744–55, <http://dx.doi.org/10.1111/jonm.12936>.
 18. Law M, Jackson D, Turner R, Rhodes K, Viechtbauer W. Two new methods to fit models for network meta-analysis with random inconsistency effects. *BMC Med Res Methodol.* 2016;16:87.
 19. Sirtori CR. The pharmacology of statins. *Pharmacol Res.* 2014;88:3–11, <http://dx.doi.org/10.1016/j.phrs.2014.03.002>.
 20. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/Apha/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019;73:e285–350, <http://dx.doi.org/10.1016/j.jacc.2018.11.003>.
 21. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment Aetiology and Management. *Eur Heart J.* 2015;36:1012–22, <http://dx.doi.org/10.1093/eurheartj/ehv043>.
 22. Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic pharmacogenomic and muscle components. *J Clin Med.* 2019;9:pii:E22, <http://dx.doi.org/10.3390/jcm9010022>.
 23. Sisson EM, Pamulapati L, Bucheit JD, Kelly MS, Dixon DL. Evolving role of non-statin therapy for the management of dyslipidemia and cardiovascular risk reduction: past present, and future. *Pharmacotherapy.* 2018;38:164–71, <http://dx.doi.org/10.1002/phar.2074>.
 24. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med.* 2015;372:2387–97, <http://dx.doi.org/10.1056/NEJMoa1410489>.
 25. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med.* 2017;376:1713–22, <http://dx.doi.org/10.1056/NEJMoa1615664>.
 26. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med.* 2018;379:2097–107, <http://dx.doi.org/10.1056/NEJMoa1801174>.
 27. Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. *Lipids Health Dis.* 2019;18:134, <http://dx.doi.org/10.1186/s12944-019-1080-x>.
 28. Olofsson SO, Borén J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. *J Intern Med.* 2005;258:395–410, <http://dx.doi.org/10.1111/j.1365-2796.2005.01556.x>.
 29. Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. *J Lipid Res.* 2013;54:2095–108, <http://dx.doi.org/10.1194/jlr.M035212>.
 30. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. *Circulation.* 1999;100:230–5, <http://dx.doi.org/10.1161/01.cir.100.3.230>.
 31. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med.* 2001;344:1959–65, <http://dx.doi.org/10.1056/NEJM200106283442601>.
 32. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med.* 2008;359:2195–207, <http://dx.doi.org/10.1056/NEJMoa0807646>.
 33. Nguyen D, Du N, Sulaica EM, Wanat MA. A review of bempedoic acid: a new drug for an old problem. *Ann Pharmacother.* 2020;16, <http://dx.doi.org/10.1177/1060028020941083>.
 34. Cicero AFG, Pontremoli R, Fogacci F, Viazzi F, Borghi C. Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. *Drug Saf.* 2020;43:727–36, <http://dx.doi.org/10.1007/s40264-020-00931-6>.
 35. Weaver DJ Jr. Uric acid and progression of chronic kidney disease. *Pediatr Nephrol.* 2019;34:801–9, <http://dx.doi.org/10.1007/s00467-018-3979-2>.